Understand the source comparison
Anti-VEGF injections vs angiogenic peptides
Anti-VEGF mechanism: Bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea) bind VEGF preventing receptor binding. Blocks pathological neovascularization in wet AMD and proliferative diabetic retinopathy. Directly inhibits vessel growth rather than
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Anti-VEGF mechanism: Bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea) bind VEGF preventing receptor binding. Blocks pathological neovascularization in wet AMD and proliferative diabetic retinopathy. Directly inhibits vessel growth rather than promoting it. Administered intravitreally every 4-8 weeks.
- BPC-157 angiogenic effects: Promotes VEGF and physiological vessel formation. Appears supporting healthy vessels not pathological leakage based on animal studies. Opposite approach, restoring circulation versus blocking it. Systemically administered meaning affects whole body not just eye. Complementary for ischemic conditions (retinal vein occlusion, non-proliferative diabetic retinopathy) where revascularization beneficial versus proliferative diseases requiring anti-VEGF.
- When each appropriate: Anti-VEGF gold standard for wet AMD and proliferative diabetic retinopathy where abnormal vessels causing vision loss. BPC-157 potentially beneficial for ischemic conditions, non-proliferative retinopathy, or supporting recovery after anti-VEGF treatment resolves active neovascularization.
- Not substitutes but addressing different pathological processes. Learn about treatment integration strategies.